SciencePANXEON blood test reportedly detects 86.8% of stage I–II pancreatic cancer cases in study
A cardiologist, citing Nature Medicine on September 16, 2026, describe results from 1,286 people in four countries—and cautions that the test is not ready for annual checkups.
TLDR
A cardiologist’s September 16, 2026 post, citing Nature Medicine, describe PANXEON as a blood test combining 10 circulating microRNAs with the CA19-9 marker. The cardiologist reports 86.8% sensitivity for stage I–II pancreatic cancer—meaning it detected that share of cases—with false positives in about 3% of low-risk people. The test was trained and tested across 1,286 people in four countries, according to the account. The cardiologist cautions that larger prospective validation is still needed before it is ready for annual checkups.